Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
Iborra M, Pérez-Gisbert J, Bosca-Watts MM, López-García A, García-Sánchez V, López-Sanromán A, Hinojosa E, Márquez L, García-López S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-Gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P; Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).. Iborra M, et al. J Gastroenterol. 2017 Jul;52(7):788-799. doi: 10.1007/s00535-016-1274-1. Epub 2016 Oct 8. J Gastroenterol. 2017. PMID: 27722996
Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
Iborra M, Gisbert JP, Bosca-Watts MM, López-García A, García-Sánchez V, López-Sanromán A, Hinojosa E, Márquez L, García-López S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-Gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P; Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).. Iborra M, et al. J Gastroenterol. 2017 Jul;52(7):875-877. doi: 10.1007/s00535-016-1293-y. J Gastroenterol. 2017. PMID: 27885420 Free article. No abstract available.
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients.
Barreiro-de Acosta M, Marín-Jiménez I, Panadero A, Guardiola J, Cañas M, Gobbo Montoya M, Modino Y, Alcaín G, Bosca-Watts MM, Calvet X, Casellas F, Chaparro M, Fernández Salazar L, Ferreiro-Iglesias R, Ginard D, Iborra M, Manceñido N, Mañosa M, Merino O, Rivero M, Roncero O, Sempere L, Vega P, Zabana Y, Mínguez M, Nos P, Gisbert JP. Barreiro-de Acosta M, et al. Gastroenterol Hepatol. 2018 Feb;41(2):118-127. doi: 10.1016/j.gastrohep.2017.10.003. Epub 2017 Dec 21. Gastroenterol Hepatol. 2018. PMID: 29275001 English, Spanish.
Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.
Taxonera C, Iborra M, Bosca-Watts MM, Rubio S, Nantes Ó, Higuera R, Bertoletti F, Martínez-Montiel P, Sierra-Ausin M, Manceñido N, Lázaro Pérez-Calle J, Algaba A, Olivares D, Alba C. Taxonera C, et al. Curr Med Res Opin. 2019 Jul;35(7):1297-1304. doi: 10.1080/03007995.2019.1579557. Epub 2019 Mar 13. Curr Med Res Opin. 2019. PMID: 30722703
Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study.
Marti-Aguado D, Ballester MP, Tosca J, Bosca-Watts MM, Navarro P, Anton R, Pascual I, Mora F, Minguez M. Marti-Aguado D, et al. United European Gastroenterol J. 2019 Oct;7(8):1042-1050. doi: 10.1177/2050640619854277. Epub 2019 May 29. United European Gastroenterol J. 2019. PMID: 31662861 Free PMC article.
39 results